Analysis of clinical application of ALPPS for hepatocellular carcinoma with mild-to-moderate liver cirrhosis
10.3760/cma.j.issn.1007-8118.2019.11.002
- VernacularTitle: ALPPS在合并轻中度肝纤维化肝细胞癌患者中的应用分析
- Author:
Chunhong LIU
1
;
Mingwu DENG
;
Siyuan QIU
;
Hongtao ZHU
;
Bangren XU
;
Xiaoming HONG
;
Ren JI
;
KC NG KELVIN
;
AC CHAN ALBERT
;
Tan To CHEUNG
;
Mau LO CHUNG
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Carcinoma, hepatocelluar;
Hepatectomy;
Associating liver partition and portal vein ligation for staged hepatectomy
- From:
Chinese Journal of Hepatobiliary Surgery
2019;25(11):806-808
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the application of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma with mild-to-moderate liver cirrhosis.
Methods:There are 14 patients with hepatocellular carcinoma underwent ALPPS at the Department of Hepatobiliary and Pancreatic Surgery, Hong Kong University-Shenzhen Hospital from April 2014 to December 2017. The clinical data was retrospectively studied. The studying objects consisted of 9 males and 5 females, aged from 26 to 71 years old with the average age of 51, all cases were of Child-Pugh grade A. The degree of liver cirrhosis, operation and postoperative complications were analyzed.
Results:All 14 patients completed the ALPPS, 1 patient died post stage 2 operation with liver failure. Comparing the groups with no liver cirrhosis (n=4) with the groups of mild liver cirrhosis (n=5) and moderate liver cirrhosis (n=5), the future liver remnant liver volume growth rates were 58%, 46% and 45.6%, respectively. The average operation intervals were 9.0, 11.2 and 12.8 days, respectively. Postoperative complications occurred in 4 patients: 2 patients with liver failure, 1 patient with intestinal obstruction, and 1 patient with hepatic ascites.
Conclusion:ALPPS for Child-Pugh grade A, hepatocellular carcinoma with mild-to-moderate liver cirrhosis treatment is safe and feasible.
